Two series of pyrazolo[3,4-
b]pyridine derivatives,
9a–
h and
14a–
h, are synthesized and evaluated for their anti-cancer potency towards Hela, MCF7, and HCT-116 cancer cell lines. Compound
9a showed the highest anticancer activity with IC
50 = 2.59
[...] Read more.
Two series of pyrazolo[3,4-
b]pyridine derivatives,
9a–
h and
14a–
h, are synthesized and evaluated for their anti-cancer potency towards Hela, MCF7, and HCT-116 cancer cell lines. Compound
9a showed the highest anticancer activity with IC
50 = 2.59 µM against Hela when compared with doxorubicin (IC
50 = 2.35 µM). Compound
14g revealed cytotoxicity IC
50 = 4.66 and 1.98 µM towards MCF7 and HCT-116 compared to doxorubicin with IC
50 = 4.57 and 2.11 µM, respectively. Compound
9a exhibited cell cycle arrest at the S phase for Hela, whereas
14g revealed an arresting cell cycle for MCF7 at G2/M phase and an arresting cell cycle at S phase in HCT-116. In addition,
9a induced a significant level of early and late apoptosis in Hela when compared with the control cells, whereas
14g induced an apoptosis in MCF7 and HCT-116, respectively. Compounds
9a (IC
50 = 26.44 ± 3.23 µM) and
14g (IC
50 = 21.81 ± 2.96 µM) showed good safety profiles on normal cell line WI-38. Compounds
9a and
14g showed good inhibition activity towards CDK2, with IC
50 = 1.630 ± 0.009 and 0.460 ± 0.024 µM, respectively, when compared with ribociclib (IC
50 = 0.068 ± 0.004). Furthermore,
9a and
14g showed inhibitory activity towards CDK9 with IC
50 = 0.262 ± 0.013 and 0.801 ± 0.041 µM, respectively, related to IC
50 of ribociclib = 0.050 ± 0.003. Docking study for
9a and
14g exhibited good fitting in the CDK2 and CDK9 active sites.
Full article